The technology can evaluate as many as 250,000 dendritic spines per month as well as simultaneously assess spine quantity and morphology in multiple brain regions.
The ESP can also be used to evaluate disease models, safety of therapeutics for central nervous system (CNS) and in vivo preclinical efficacy.
PsychoGenics president and CEO Emer Leahy said the company believes that ESP offers a powerful approach to drug discovery in CNS diseases and it is pleased to partner with Afraxis to offer the technology to its fee-for-service clients and partners.
"This expansion of PsychoGenics’ service offerings enables our clients and partners to identify drug candidates with a higher likelihood of success in a time and cost efficient manner," Leahy added.
Afraxis president and CEO Jay Lichter said, "ESP is a robust platform for drug discovery in CNS diseases that generates highly reproducible results through large data sets and redundant analysis using objective spine morphology classification criteria."